GlobeNewswire PharmaOriginal article
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Phase 2positivetrevogrumabsemaglutidePositive
AI Analysis
Summary
Phase 2 COURAGE trial demonstrates that trevogrumab prevented 70% of muscle loss in a predefined MRI substudy during semaglutide-induced weight loss treatment. The positive data supports trevogrumab's potential as a therapeutic intervention to preserve lean mass in GLP-1 receptor agonist users.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Trevogrumab prevented 70% of muscle loss associated with semaglutide treatment in predefined MRI substudy
Importance:7/10
Sentiment:
0.75
Phase 2 dataMuscle lossGLP-1 agonistWeight lossMRI substudy
Read the original article
Published by GlobeNewswire Pharma on October 1, 2026 3:30 PM